Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.930
-0.140-1.39%
Volume:45.90M
Turnover:453.22M
Market Cap:114.41B
PE:24.96
High:10.040
Open:9.955
Low:9.670
Close:10.070
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.55
T/O Rate:0.40%
Dividend:0.29
Dividend Rate:2.92%
EPS(LYR):0.398
ROE:20.90%
ROA:10.70%
PB:2.60
PE(LYR):24.96
PS:3.12

Loading ...

CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection

Reuters
·
Aug 27

CSPC Pharmaceutical - Pharma Obtains China Clinical Trial Approval for Syh2092 Injection

THOMSON REUTERS
·
Aug 27

CSPC Pharmaceutical - Highly Potent Amylin Receptor Agonist (Syh2092 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Aug 27

CSPC PHARMA: DFZQ Disposes of Shares, Long Position Falls to 4.93%

HK Disclosure
·
Aug 27

CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus

Simply Wall St.
·
Aug 27

CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint

MT Newswires Live
·
Aug 26

CSPC Pharma’s EGFR-Targeted ADC SYS6010 Achieves Primary PFS Endpoint in Phase III NSCLC Trial

Bulletin Express
·
Aug 26

CSPC Pharmaceutical Gains U.S. FDA Fast Track Status for Novel PD-1/IL-15 Fusion Protein in Hard-to-Treat Metastatic Colorectal Cancer

Bulletin Express
·
Aug 26

CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment

Stock News
·
Aug 26

CSPC Pharma Says FDA Grants Fast Track Status to Sys6090 for MSS/pMMR Metastatic Colorectal Cancer

Reuters
·
Aug 26

CSPC Pharma's SYS6010 Achieves Primary Endpoint in Phase III Trial for EGFR-Mutant NSCLC Patients

Stock News
·
Aug 26

CSPC Pharmaceutical - Sys6090 (Jmt108) Granted Fast Track Designation by U.S. FDA for Mss/Pmmr Mcrc

THOMSON REUTERS
·
Aug 26

CSPC Pharmaceutical - Sys6010 Meets Primary Endpoint of Progression-Free Survival in Phase Iii Synstar-01 Study

THOMSON REUTERS
·
Aug 26

CSPC Pharmaceutical Group Stock Rallies 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 26

Sihuan Pharmaceutical H1 Profit Jumps on Medical Aesthetics Unit Strength

Reuters
·
Aug 26

Movement Alert|CSPC PHARMA Rises 3.13% in Regular Trading, RSV Vaccine Receives FDA Clinical Trial Approval While Multiple Banks Raise Target Prices

Market Focus
·
Aug 26

CSPC Pharma secures U.S. FDA clearance for Phase I trial of second recombinant RSV vaccine SYS6057

Bulletin Express
·
Aug 25

CSPC Pharma's Recombinant RSV Vaccine Wins US Clinical Trial Clearance

Stock News
·
Aug 25

CSPC Says FDA Clears RSV Vaccine Candidate SYS 6057 for US Clinical Trial

Reuters
·
Aug 25

CSPC Pharmaceutical - Recombinant Respiratory Syncytial Virus Vaccine (Sys6057) Obtains Clinical Trial Approval in U.S.

THOMSON REUTERS
·
Aug 25